最新
热门
$CureVac(CVAC.US$
截至2024年,CureVac的 COVID-19 疫苗正在进行临床试验。目前,与葛兰素史克合作开发的第二代 mRNA COVID-19 疫苗正在进行二期试验。
进展和试验数据
在二期临床试验中,CureVac的单价疫苗 CV0601 和二价疫苗 CV0701 均显示出积极的结果。针对 Omicron BA.4-5 变体的单价疫苗显示出了一种...
截至2024年,CureVac的 COVID-19 疫苗正在进行临床试验。目前,与葛兰素史克合作开发的第二代 mRNA COVID-19 疫苗正在进行二期试验。
进展和试验数据
在二期临床试验中,CureVac的单价疫苗 CV0601 和二价疫苗 CV0701 均显示出积极的结果。针对 Omicron BA.4-5 变体的单价疫苗显示出了一种...
已翻译
![Covid FliRT 已传播到 14 个国家。CureVac 的反应如何?](https://sgsnsimg.moomoo.com/sns_client_feed/104293256/20240524/1716540000087-random4180-104293256-android-org.jpeg/thumb?area=104&is_public=true)
1
4
$Moderna(MRNA.US$ stock gained 7.8% Thursday, its virtual R&D day, which began at 8 a.m. Eastern. It plans to announce the development of a vaccine candidate that will protect against Covid-19 and the flu, to be known as mRNA-1073.
Moderna was a very different company at the time of its last virtual R&D day in September of 2020. Still a clinical-stage company at the time, Moderna had no authorized or approved products. That changed months later, when the U.S. Food and Drug Administration authorized Moderna’s Covid-19 vaccine, which is expected to bring in $20.1 billion in revenues this year alone.
Its stock price has been up more than 300% this year.
Just to mention, another vaccine maker $诺瓦瓦克斯医药(NVAX.US$ had also initiated an early-stage study to test its combined flu and COVID-19 vaccine. However, the same scenario didn't show on its stock price. Kinda tricky.
Source: Moderna Stock Jumped Because It Just Unveiled a Two-in-One Vaccine for Covid and the Flu
Moderna was a very different company at the time of its last virtual R&D day in September of 2020. Still a clinical-stage company at the time, Moderna had no authorized or approved products. That changed months later, when the U.S. Food and Drug Administration authorized Moderna’s Covid-19 vaccine, which is expected to bring in $20.1 billion in revenues this year alone.
Its stock price has been up more than 300% this year.
Just to mention, another vaccine maker $诺瓦瓦克斯医药(NVAX.US$ had also initiated an early-stage study to test its combined flu and COVID-19 vaccine. However, the same scenario didn't show on its stock price. Kinda tricky.
Source: Moderna Stock Jumped Because It Just Unveiled a Two-in-One Vaccine for Covid and the Flu
![Daily Poll: 1+1= Stonk? Moderna stock jumped 7% after unveiling new vaccine.](https://ussnsimg.moomoo.com/1631244967561-77777000-android-org.gif/thumb)
39
17
医药股再次开始上涨只是时间问题。随着各种生物技术公司都推出了疫苗,预计主要制药股将受益于Moderna,辉瑞等公司在过去一年中一直在上涨,但在过去的两个月中,由于疫苗销售造成的财务影响远高于分析师的预期,它们的股价几乎呈指数级增长。
投资者现在关注疫苗收入的未来可持续性。
辉瑞指出,预计将在今年晚些时候建议进行第三次加强注射,而突变菌株病例数的增加可能会使对更多疫苗的需求居高不下。本月,Moderna将其权重从0.85%提高到3%的上限,而辉瑞将其权重从0.47%提高到1.96%。医疗保健行业在BUZZ指数中的总体权重从5.7%上升至9.8%,表明投资者对该行业的信心增强...
投资者现在关注疫苗收入的未来可持续性。
辉瑞指出,预计将在今年晚些时候建议进行第三次加强注射,而突变菌株病例数的增加可能会使对更多疫苗的需求居高不下。本月,Moderna将其权重从0.85%提高到3%的上限,而辉瑞将其权重从0.47%提高到1.96%。医疗保健行业在BUZZ指数中的总体权重从5.7%上升至9.8%,表明投资者对该行业的信心增强...
已翻译
Moderna COVID-19 疫苗 $Moderna(MRNA.US$ 12 岁及以上儿童获得加拿大卫生部批准!
疫苗股将继续上涨至顶部,无疑是值得买入的 ✅
$Moderna(MRNA.US$其神奇的mRNA技术似乎有望迎合市场,该技术可以更快地适应新变种。这意味着Moderna利润丰厚的Covid-19疫苗收入可能会在未来可预见的将来持续下去。...
疫苗股将继续上涨至顶部,无疑是值得买入的 ✅
$Moderna(MRNA.US$其神奇的mRNA技术似乎有望迎合市场,该技术可以更快地适应新变种。这意味着Moderna利润丰厚的Covid-19疫苗收入可能会在未来可预见的将来持续下去。...
已翻译
9
5
在我看来,疫苗股票仍然被认为波动很大。许多公司仍在尝试不同的方法来制造最好的疫苗,这种疫苗的副作用最小,对抗Covid效果最好。目前,mRNA 疫苗像 $辉瑞(PFE.US$ 和 $Moderna(MRNA.US$ 是目前市场上最好的疫苗,在Covid病例不断增加的情况下,无疑将获得FDA的批准,以增强人们接种疫苗的信心。推动人们接种这些高效疫苗更像是一种很难推销的方式。因此,在短期内,这些mRNA公司将显示出看涨趋势,但有时仍会波动,因为有负面消息称此类疫苗可能导致死亡和心脏病增加。冠状病毒疫苗的未来肯定仍然不确定。谁知道是否会突然有竞争对手想出最好的疫苗...
已翻译
8
Net buying of More than $400m of American depositary receipts by US retail investors of Chinese companies in the past week was the highest in five years, peaking on Monday, led by e-commerce giant Alibaba The research house's Vanda Rack unit is understood to monitor retail trading activity in 9,000 individual stocks and ETFs in the US.
According to Vanda, U.S. retail buying of Alibaba shares was more than double that of pharmaceutical giant Pfizer over the same period, even though Pfizer received full approval for its coronavirus vaccine from the U.S. Food and Drug Administration on Monday....
According to Vanda, U.S. retail buying of Alibaba shares was more than double that of pharmaceutical giant Pfizer over the same period, even though Pfizer received full approval for its coronavirus vaccine from the U.S. Food and Drug Administration on Monday....
1
(1) Delta 变体
截至发稿时,WorlsMeter的实时数据显示,全球有2.14亿例确诊病例和447万例死亡。
Delta 变种传播、第三波疫情、COVID-19 病例激增、COVID-19 疫情请更新和股市影响、最新确诊病例、死亡、印度病例、新变种的影响、对美国股市的影响、对欧洲 DAX 指数的影响
美国新增确诊/住院病例数量急剧上升
...
截至发稿时,WorlsMeter的实时数据显示,全球有2.14亿例确诊病例和447万例死亡。
Delta 变种传播、第三波疫情、COVID-19 病例激增、COVID-19 疫情请更新和股市影响、最新确诊病例、死亡、印度病例、新变种的影响、对美国股市的影响、对欧洲 DAX 指数的影响
美国新增确诊/住院病例数量急剧上升
...
已翻译
![美国新确诊的病例数量急剧上升](https://ussnsimg.moomoo.com/8092097666224953040.jpg/thumb)
1
Kindergarten Big Bro : 那么到6月底会变成6吗?感觉收益对股票的影响不大
Tom2808 Kindergarten Big Bro: 我觉得它没有吸引足够的买家购买这只股票。一切似乎都很好...但是很慢
Chen trader moo楼主 Kindergarten Big Bro: 我认为它会很缓慢,但作为一项长期投资,我认为这是一只IPO股票,将来肯定会带来丰厚的回报。
Kindergarten Big Bro Chen trader moo楼主: 如何查看这只股票的首次公开募股?